格隆汇9月17日｜华创证券研报指出，迈瑞医疗25H1归母净利润50.69亿元（-32.96%），单25Q2归母净 利润24.40亿元（-44.55%）。国际市场增长稳健，国内市场短期承压静待拐点。随着医疗设备更新项目 启动，上半年招标活动已迎来复苏，预计国内市场第三季度将明显改善，如期迎来拐点。2025H1公司 新推出8个化学发光试剂产品，NMPA上市产品总数增至88 个，同时MT8000流水线新增订单185套、新 增装机近100套，全年装机有望达200套。此外今年将是微创外科核心业务超声刀、腔镜吻合器等高值耗 材在国内的放量元年，将为该业务板块的长期增长注入强劲新动能。根据DCF模型测算，给予公司整体 估值3539亿元，目标价约292元，对应2026年PE 为27X，维持"推荐"评级。 ...

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first half of 2025, but there are signs of recovery in the second quarter, particularly in the domestic market, while overseas business continues to grow steadily [1][2]. Financial Performance - In H1 2025, the company achieved operating revenue of 16.743 billion yuan, a year-on-year decrease of 18.45%, and a net profit attributable to shareholders of 5.069 billion yuan, down 32.96% [1]. - In Q2 2025, the company recorded operating revenue of 8.506 billion yuan, a year-on-year decline of 23.77%, and a net profit of 2.440 billion yuan, down 44.55% [1]. Market Analysis - Domestic revenue in H1 2025 was 8.411 billion yuan, a decrease of 33.38%, primarily due to extended bidding income recognition cycles and a skewed revenue base from the previous year [2]. - The overseas market generated revenue of 8.332 billion yuan, an increase of 5.39%, with its revenue share rising to 49.77% [2]. Business Segment Performance - The in-vitro diagnostics segment reported revenue of 6.424 billion yuan, down 16.11%, but international business saw double-digit growth [2]. - The life information and support segment generated revenue of 5.479 billion yuan, down 31.59%, with international business accounting for 67% of the segment [2]. - The medical imaging segment achieved revenue of 3.312 billion yuan, down 22.51%, with international business share increasing to 62% [2]. AI Business Development - The company is advancing its AI business with the launch of the "Qiyuan Critical Care Model" and ongoing upgrades to the "Sanrui" system, enhancing its offerings for high-end clients [3]. - In H1 2025, the "Ruijian Ecological" laboratory solutions were installed in 210 new hospitals, totaling nearly 800, with about 80% being tertiary hospitals [3]. - The "Ruizhi Ecological" solutions added 108 new projects, covering 38 top-tier hospitals, with over 1,000 hospitals reached cumulatively [3]. Profit Forecast - The company forecasts total operating revenue of 37.887 billion yuan, 43.262 billion yuan, and 49.914 billion yuan for 2025-2027, with year-on-year growth rates of 3.16%, 14.19%, and 15.38% respectively [3]. - Net profit attributable to shareholders is projected to be 11.909 billion yuan, 13.852 billion yuan, and 16.230 billion yuan for the same period, with growth rates of 2.07%, 16.31%, and 17.17% respectively [3].